CD19 and lymphoma: Apt-Dox complex, however, mainly produced a robust cytotoxicity towards CD19-positive lymphoma cells (Figure 9A), and significantly reduced the cytotoxicity to CD19-negative cells (Figure 9B, p<0.01).